Ocrevus Alternatives Compared
Ocrevus | Betaseron | Kesimpta |
|
---|
Ocrevus (ocrelizumab) | Betaseron (interferon beta-1b) | Kesimpta (ofatumumab) |
|
|||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Ocrevus is a CD20 monoclonal antibody that causes B-cells to self-destruct or disintegrate, reducing inflammation in people with MS. After an initial loading dose, it is given by IV infusion every... View more |
Prescription only
Prescribed for Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Multiple Sclerosis, Colorectal Cancer. Betaseron may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Multiple Sclerosis. Kesimpta may also be used for purposes not listed in this medication guide. |
Related suggestions |
|||||||||||||||||||||||
More about Ocrevus (ocrelizumab) | More about Betaseron (interferon beta-1b) | More about Kesimpta (ofatumumab) | ||||||||||||||||||||||||
Generic Status | ||||||||||||||||||||||||||
No lower-cost generic available |
No lower-cost generic available |
No lower-cost generic available |
||||||||||||||||||||||||
Ratings & Reviews | ||||||||||||||||||||||||||
Ocrevus has an average rating of 4.5 out of 10 from a total of 152 ratings on Drugs.com. 33% of reviewers reported a positive effect, while 52% reported a negative effect. |
Betaseron has an average rating of 7.0 out of 10 from a total of 7 ratings on Drugs.com. 57% of reviewers reported a positive effect, while 14% reported a negative effect. |
Kesimpta has an average rating of 6.5 out of 10 from a total of 53 ratings on Drugs.com. 48% of reviewers reported a positive effect, while 25% reported a negative effect. |
||||||||||||||||||||||||
Drug Class | ||||||||||||||||||||||||||
Side Effects | ||||||||||||||||||||||||||
Common side effects include:
See also: Ocrevus side effects in more detail. |
Common side effects include:
See also: Betaseron side effects in more detail. |
See also: Kesimpta side effects in more detail. |
||||||||||||||||||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Ocrevus prices |
View all Betaseron prices |
View all Kesimpta prices |
||||||||||||||||||||||||
Dosage Form(s) Available | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
Brand Names | ||||||||||||||||||||||||||
N/A |
Other interferon beta-1b brands include: Extavia | Other ofatumumab brands include: Arzerra | ||||||||||||||||||||||||
Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||||||||||
624 hours |
4.3 hours |
1476 hours |
||||||||||||||||||||||||
CSA Schedule ** View glossary of terms | ||||||||||||||||||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
Pregnancy Category | ||||||||||||||||||||||||||
Summary unavailable. See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||||||||||||||||||
Drug Interactions | ||||||||||||||||||||||||||
A total of 381 drugs are known to interact with Ocrevus:
|
A total of 314 drugs are known to interact with Betaseron:
|
A total of 155 drugs are known to interact with Kesimpta:
|
||||||||||||||||||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
Disease Interactions | ||||||||||||||||||||||||||
First Approval Date | ||||||||||||||||||||||||||
March 28, 2017 |
July 23, 1993 |
N/A |
||||||||||||||||||||||||
WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||||||||||
N/A |
N/A |
N/A |
||||||||||||||||||||||||
More Information | ||||||||||||||||||||||||||
Patient resources | ||||||||||||||||||||||||||
Professional Resources | ||||||||||||||||||||||||||
Related Treatment Guide | ||||||||||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.